



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT #

12/13  
JM

RECEIVED 8/7/02

JUL 31 2002

TECH CENTER 1600/2900

Application of

Bert Vogelstein, *et. al.*

Serial No. 09/780,566

Filed: February 12, 2001

For: CDK4 IS A TARGET OF c-MYC

) Group Art Unit: 1642

) Examiner: Davis, N.A.

) Docket No. 01107.00092

AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed June 18, 2002, applicants request entry of the following amendments and reconsideration of the patentability of rejected claims 25-32.

Appendix 1 is a version of amended claims, with markings to show changes made.

IN THE CLAIMS:

Please cancel claims 1-24 and 33-34. Please amend claims 25 and 32 as follows.

25. (Amended) A method of screening compounds to identify as candidate agents those which have anti-cancer activity, comprising the steps of:

contacting a cell which has a genetic alteration which dysregulates *c-MYC* expression with a test compound;

measuring activity of CDK4 in the cell, wherein a test compound which inhibits activity of CDK4 is identified as a candidate agent with anti-cancer activity.

32. (Amended) The method of claim 25 wherein the cell has a truncating mutation in *APC*.